Cell differentiation modulation in cancer cells

Cell differentiation modulation in cancer cells, commonly referred to as differentiation therapy, is a therapeutic strategy aimed at forcing malignant cells to resume the maturation process into terminal, non-dividing states rather than directly inducing cytotoxicity. This process is most famously exemplified in the treatment of acute promyelocytic leukemia (APL), where all-trans retinoic acid (ATRA) targets the PML-RARA fusion protein to overcome a differentiation block. Beyond APL, modern approaches target mutant enzymes like isocitrate dehydrogenase 1 and 2 (IDH1/2) in myeloid malignancies to reverse epigenetic silencing and promote cellular maturation. By targeting the underlying developmental arrest of a tumor, this strategy aims to reduce the pool of self-renewing cancer stem cells. It represents a shift from traditional chemotherapy by focusing on the restoration of normal cellular function and homeostatic control. However, the rapid maturation of large cell populations can lead to severe clinical complications, such as differentiation syndrome.

Other names

Differentiation therapyTumor differentiation inductionCancer cell reprogrammingPro-differentiation therapy

Drugs modulate differentiation by acting as agonists for nuclear receptors (e.g., RARα) or inhibitors of enzymes (e.g., IDH1/2, HDACs) that maintain a block in cellular maturation, thereby forcing malignant blasts to mature into functional, non-proliferative cells.